Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://cr.elmerpub.com

Review

Volume 17, Number 2, April 2026, pages 61-71

Optimization and Real-World Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: A Contemporary Clinical Review

↓ Figure 1. Practical phenotype-guided framework for rapid initiation and optimization of guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF). The algorithm emphasizes early initiation of all four foundational therapies (“four drugs in 4 weeks”) followed by structured up-titration and phenotype-specific prioritization. ARNI: angiotensin receptor–neprilysin inhibitor; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium–glucose cotransporter 2 inhibitor; BP: blood pressure; HR: heart rate; ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy; LVEF: left ventricular ejection fraction; SBP: systolic blood pressure.

↓ Figure 2. Stepwise treatment algorithm for patients with symptomatic heart failure with reduced ejection fraction (HFrEF). ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor–neprilysin inhibitor; CRT: cardiac resynchronization therapy; HR: heart rate; ICD: implantable cardioverter-defibrillator; LVAD: left ventricular assist device; LVEF: left ventricular ejection fraction.

↓ **Table 1.** Foundational Guideline-Directed Medical Therapy in HFrEF
Drug class	Key agents	Main clinical benefit
ARNI: angiotensin receptor–neprilysin inhibitor; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; SGLT2: sodium–glucose cotransporter 2; HF: heart failure; HFrEF: heart failure with reduced ejection fraction.
ARNI/ACEi/ARB	Sacubitril/valsartan; enalapril; losartan	Reduced mortality, hospitalization, and adverse remodeling
Evidence-based β-blockers	Carvedilol; metoprolol succinate; bisoprolol	Reduced mortality and sudden cardiac death; reverse remodeling
Mineralocorticoid receptor antagonists	Spironolactone; eplerenone	Reduced mortality and hospitalization; antifibrotic effects
SGLT2 inhibitors	Dapagliflozin; empagliflozin	Reduced HF hospitalization and cardiovascular death, irrespective of diabetes

↓ Table 1. Foundational Guideline-Directed Medical Therapy in HFrEF

Drug class

Key agents

Main clinical benefit

ARNI: angiotensin receptor–neprilysin inhibitor; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; SGLT2: sodium–glucose cotransporter 2; HF: heart failure; HFrEF: heart failure with reduced ejection fraction.

ARNI/ACEi/ARB

Sacubitril/valsartan; enalapril; losartan

Reduced mortality, hospitalization, and adverse remodeling

Evidence-based β-blockers

Carvedilol; metoprolol succinate; bisoprolol

Reduced mortality and sudden cardiac death; reverse remodeling

Mineralocorticoid receptor antagonists

Spironolactone; eplerenone

Reduced mortality and hospitalization; antifibrotic effects

SGLT2 inhibitors

Dapagliflozin; empagliflozin

Reduced HF hospitalization and cardiovascular death, irrespective of diabetes

↓ **Table 2.** Initiation Criteria, Contraindications, and Monitoring for GDMT in HFrEF
Therapy	Key initiation criteria	Major contraindications	Monitoring parameters
HFrEF: heart failure with reduced ejection fraction; GDMT: guideline-directed medical therapy; ARNI: angiotensin receptor–neprilysin inhibitor; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist; SGLT2: sodium–glucose cotransporter 2; BP: blood pressure; HR: heart rate; SBP: systolic blood pressure; AV: atrioventricular.
ARNI/ACEi/ARB	SBP ≥ 90–100 mm Hg; stable renal function	History of angioedema; pregnancy; severe hyperkalemia	BP, serum creatinine, potassium
β-blockers	Euvolemic, clinically stable patient	Cardiogenic shock; severe bradycardia; advanced AV block	HR, BP, symptoms of congestion
MRA	eGFR ≥ 30 mL/min/1.73 m²; K ≤ 5.0 mmol/L	Severe renal dysfunction; hyperkalemia	Potassium, renal function
SGLT2 inhibitors	Stable HFrEF with or without diabetes	Type 1 diabetes; active ketoacidosis	Renal function, volume status

↓ Table 2. Initiation Criteria, Contraindications, and Monitoring for GDMT in HFrEF

Therapy

Key initiation criteria

Major contraindications

Monitoring parameters

HFrEF: heart failure with reduced ejection fraction; GDMT: guideline-directed medical therapy; ARNI: angiotensin receptor–neprilysin inhibitor; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist; SGLT2: sodium–glucose cotransporter 2; BP: blood pressure; HR: heart rate; SBP: systolic blood pressure; AV: atrioventricular.

ARNI/ACEi/ARB

SBP ≥ 90–100 mm Hg; stable renal function

History of angioedema; pregnancy; severe hyperkalemia

BP, serum creatinine, potassium

β-blockers

Euvolemic, clinically stable patient

Cardiogenic shock; severe bradycardia; advanced AV block

HR, BP, symptoms of congestion

MRA

eGFR ≥ 30 mL/min/1.73 m²; K ≤ 5.0 mmol/L

Severe renal dysfunction; hyperkalemia

Potassium, renal function

SGLT2 inhibitors

Stable HFrEF with or without diabetes

Type 1 diabetes; active ketoacidosis

Renal function, volume status

↓ **Table 3.** Implementation Barriers to Optimal GDMT and Targeted Strategies for Resolution
Barrier category	Clinical scenario	Mechanistic concern	Targeted implementation strategy
GDMT: guideline-directed medical therapy; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium–glucose cotransporter 2 inhibitor; RAAS: renin–angiotensin–aldosterone system.
Hemodynamic limitation	Borderline blood pressure	Risk of symptomatic hypotension	Prioritize SGLT2i and MRA; reduce non-prognostic vasodilators; adjust diuretics before down-titrating GDMT
Renal dysfunction	Rising creatinine after RAAS initiation	Fear of progressive kidney injury	Accept mild transient increase; reassess volume status; continue therapy with close monitoring
Hyperkalemia	Elevated potassium during RAAS/MRA therapy	Risk of arrhythmia	Dose adjustment; dietary counseling; potassium binders; avoid unnecessary discontinuation
Persistent congestion	Ongoing edema or dyspnea	Misattribution to GDMT intolerance	Optimize loop diuretics; confirm euvolemia before limiting disease-modifying therapy
Clinical inertia	Delay in initiating multiple therapies	Concern about polypharmacy or tolerability	Implement “four drugs in 4 weeks” strategy; protocol-driven low-dose initiation; follow-up within 1–2 weeks
Fragmented follow-up	Lack of structured reassessment	Failure to titrate toward target doses	Multidisciplinary HF clinics; nurse-led titration pathways; scheduled laboratory surveillance
Elderly or frail phenotype	Advanced age with comorbidities	Fear of intolerance or falls	Start low, titrate slowly; deprescribe non-essential drugs; shared decision-making

↓ Table 3. Implementation Barriers to Optimal GDMT and Targeted Strategies for Resolution

Barrier category

Clinical scenario

Mechanistic concern

Targeted implementation strategy

GDMT: guideline-directed medical therapy; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium–glucose cotransporter 2 inhibitor; RAAS: renin–angiotensin–aldosterone system.

Hemodynamic limitation

Borderline blood pressure

Risk of symptomatic hypotension

Prioritize SGLT2i and MRA; reduce non-prognostic vasodilators; adjust diuretics before down-titrating GDMT

Renal dysfunction

Rising creatinine after RAAS initiation

Fear of progressive kidney injury

Accept mild transient increase; reassess volume status; continue therapy with close monitoring

Hyperkalemia

Elevated potassium during RAAS/MRA therapy

Risk of arrhythmia

Dose adjustment; dietary counseling; potassium binders; avoid unnecessary discontinuation

Persistent congestion

Ongoing edema or dyspnea

Misattribution to GDMT intolerance

Optimize loop diuretics; confirm euvolemia before limiting disease-modifying therapy

Clinical inertia

Delay in initiating multiple therapies

Concern about polypharmacy or tolerability

Implement “four drugs in 4 weeks” strategy; protocol-driven low-dose initiation; follow-up within 1–2 weeks

Fragmented follow-up

Lack of structured reassessment

Failure to titrate toward target doses

Multidisciplinary HF clinics; nurse-led titration pathways; scheduled laboratory surveillance

Elderly or frail phenotype

Advanced age with comorbidities

Fear of intolerance or falls

Start low, titrate slowly; deprescribe non-essential drugs; shared decision-making